

Kidney360

July 2021 • Vol. 2 • No. 7

Editorial

1076 Living Organ Donor Hesitancy about COVID-19 Vaccines: A New Kind of “Source Control Issue”

Margaret R. Jorgenson

See related article on page 1132.

Debates in Nephrology

1078 Corticosteroids Should Be Used To Treat Slowly Progressive IgA Nephropathy: PRO

Amanda M. Cunningham and Heather N. Reich

See related debate on page 1081 and commentary on page 1084.

1081 Corticosteroids Should Be Used to Treat Slowly Progressive IgA Nephropathy: CON

Jonathan Barratt

See related debate on page 1078 and commentary on page 1084.

Moderator Commentary

1084 Corticosteroids Should Be Used to Treat Slowly Progressive IgA Nephropathy: COMMENTARY

Kirk N. Campbell

See related debates on pages 1078 and 1081.

Original Investigation

Acid/Base and Electrolyte Disorders

1087 Increased Mortality Associated with Hypermagnesemia in Severe COVID-19 Illness

Jacob S. Stevens, Andrew A. Moses, Thomas L. Nickolas, Syed Ali Husain and Sumit Mohan

Acute Kidney Injury and ICU Nephrology

1095 Expression of ACE2 in the Intact and Acutely Injured Kidney

Karl A. Nath, Raman Deep Singh, Joseph P. Grande, Vesna D. Garovic, Anthony J. Croatt, Allan W. Ackerman, Michael A. Barry, and Anupam Agarwal

Chronic Kidney Disease

1107 Outcomes among Hospitalized Chronic Kidney Disease Patients with COVID-19

Minesh Khatri, David M. Charytan, Sam Parnia, Christopher M. Petrilli, Jeffrey Michael, David Liu, Vasishta Tatapudi, Simon Jones, Judith Benstein, and Leora I. Horwitz

Dialysis

1115 Stakeholder-Guided Development of Dialysis Vascular Access Education Materials

Adeline Dorough, Julia H. Narendra, Caroline Wilkie, Akhil Hegde, Kawan Swain, Emily H. Chang, Terence Oliver, and Jennifer E. Flythe

NephroPharmacology

1124 G protein- and β -arrestin Signaling Profiles of Endothelin Derivatives at the Type A Endothelin Receptor

Xinyu Xiong, Nour Nazo, Ritika Revoori, Sudarshan Rajagopal, and Matthew A. Sparks

Transplantation

1132 Living Organ Donor Perspectives and Sources of Hesitancy about COVID-19 Vaccines

Meera N. Harhay, Ann C. Klassen, Hasan Zaidi, Michael Mittelman, Rebecca Bertha, Roslyn B. Mannon, and Krista L. Lentine

See related editorial on page 1076.

1141 Long-Term Impact of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients: A 5-Year Follow-Up Observational Cohort Study

Tania Salehi, Nicholas J. Montarello, Nishant Juneja, Michael B. Stokes, Daniel J. Scherer, Kerry F. Williams, David King, Ewan Macaulay, Christine H. Russell, Santosh A. Olakkengil, Robert P. Carroll, Randall J. Faull, Karen S.L. Teo, Stephen P. McDonald, Matthew I. Worthley, Patrick T. Coates, and Nitesh N. Rao

Brief Communication

Cystic Kidney Disease

1148 Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease

Taro Akihisa, Shun Manabe, Hiroshi Kataoka, Shiho Makabe, Rie Yoshida, Yusuke Ushio, Kentaro Watanabe, Masayo Sato, Ken Tsuchiya, Toshio Mochizuki, and Kosaku Nitta

Innovative Technology and Methodology

Acute Kidney Injury and ICU Nephrology

1152 Protocol for Local On-Site Dialysate Production for Continuous Renal Replacement Therapy during the COVID-19 Pandemic

Andrew A. Moses, Jacob S. Stevens, Derek Fine, Robert Carrera, Alina Li, Chirag R. Parikh, and Sumit Mohan

Clinical Research Methods

1156 Confounding in Observational Studies Evaluating the Safety and Effectiveness of Medical Treatments

Magdalene M. Assimon

Global Perspective

1160 Global Perspective on Kidney Transplantation: Turkey

Oya Andacoglu and Fazil Tuncay Aki

1163 Global Perspective on Kidney Transplantation: Thailand

Nuttasith Larpparisuth, Wisit Cheungpasitporn, and Adisorn Lumpaopong

Perspective

1166 Strategies for Continuous Renal Replacement Therapy De-escalation

Samir C. Gautam, Nityasree Srialluri, and Bernard G. Jaar

1170 A Perspective on the Metabolic Potential for Microbial Contributions to Urolithiasis

Jose Agudelo and Aaron W. Miller

1174 Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?

Niralee Patel, Judy Hindi, and Samira S. Farouk

Review Article

1179 Risks and Benefits of Kidney Transplantation during the COVID-19 Pandemic: Transplant or Not Transplant?

Maria Ajaimy, Luz Liriano-Ward, Jay A. Graham, and Enver Akalin

1188 Improving Clearance for Renal Replacement Therapy

Seolhyun Lee, Tammy L. Sirich, and Timothy W. Meyer

1196 Single Cell Technologies: Beyond Microfluidics

Haikuo Li and Benjamin D. Humphreys

Clinical Images in Nephrology and Dialysis

1205 An Atypical Kidney-Related Presentation of Multiple Myeloma

Monique Pereira Rêgo Muniz, João Batista da Silva Neto, and Gyl Eanes Silva

1207 An Unusual Cause of Kidney Allograft Dysfunction

Paul E. Rosenstiel, Glen S. Markowitz, and Brigani Amante

On the Cover

Localization of renal ACE2 and NGAL protein expression in the kidney two days after IRI (18 min). Immunofluorescence staining for DAPI (blue), ACE2 (red), and NGAL (green) in kidneys of mice two days after IRI. There is reduced tubular ACE2 staining in kidneys of mice subjected to IRI accompanied by increased NGAL staining in tubules. Adapted from figure 2, panel B in "Expression of ACE2 in the Intact and Acutely Injured Kidney" by Karl A. Nath, Raman Deep Singh, Joseph P. Grande, Vesna D. Garovic, Anthony J. Croatt, Allan W. Ackerman, Michael A. Barry and Anupam Agarwal. *KIDNEY*360 2: 1095–1106, 2021. DOI: 10.34067/KID.0001562021.